Aravive — Technical Presentation (September 2019)
16 slides from Aravive's technical presentation, Sep 27, 2019
Slide 1: Phase 1B/2 Study of AVB500 in Combination with PAC and PLD in Platinum Resistant Recurrent Ovarian Cancer
Phase 1B/2 Study of AVB500 (High Affinity Inhibitor of GAS6/AXL Path) in Combination with PAC and PLD in Platinum Resistant Recurrent Ovarian Cancer (NCT03639246) Abstract 6602 Authors: B. Monk1, R. Coleman2, K. Moore3, K. Fuh4, L. Bonifacio5, G. McIntyre5, D. Prohaska5, A. Giaccia5, M.J. Baker5, R.
Slide 2: Disclosure Slide
DISCLOSURE SLIDE All authors are either employees of Aravive, Inc. or paid consultants to Aravive, Inc. Company logo
Slide 3: AXL Tyrosine Kinase Promotes Invasion, Metastasis, and Resistance
AXL Tyrosine Kinase Promotes Invasion, Metastasis, and Resistance AXL is a member of tyrosine kinases that include Tyro3, AXL, and Mer (TAMs) AXL is activated by a single ligand, growth arrest–specific 6 (GAS6); Mer and Tyro3 can be activated by GAS6 and Protein S 1 Upregulated in many cancers 2, AX
Slide 4: GAS6/AXL Signaling Critical in Resistant Metastatic Ovarian Cancer
GAS6/AXL Signaling Critical in Resistant Metastatic Ovarian Cancer AXL in 0% (0/10) of normal ovarian tissue AXL in 73% (219/297) ovarian tumor samples including low grade serous, endometroid and advanced stage tumors1 Preclinical in vitro 1,2,3 AXL inhibition decreases invasion/migration Preclinica
Slide 5: AVB500 Inhibits AXL Signaling by Neutralizing GAS6, Sole Ligand for AXL
AVB500 Inhibits AXL Signaling by Neutralizing GAS6, Sole Ligand for AXL AXL-Fc protein engineered for very high affinity for GAS6 ~200 fold greater than native AXL Favorable safety and PK profile GAS6 not needed by normal tissue GLP preclinical studies demonstrate ≥ 30-fold safety margin (relative t
Slide 6: AVB500 Demonstrated Activity in Multiple Preclinical Platinum-Resistant Ovarian Cancer Models
AVB500 Demonstrated Activity in Multiple Preclinical Platinum-Resistant Ovarian Cancer Models Single agent activity, synergistic with DNA damaging agent in multiple PROC models (OVCAR8 and SKOV3.IP) at 1mg/kg daily, a regimen that suppressed sGAS6 for 24h. Lower doses did not demonstrate same effect
Slide 7: Serum Biomarker-Guided Dose Escalation in First in Human Study Conducted in Healthy Volunteers
Serum Biomarker-Guided Dose Escalation in First in Human Study Conducted in Healthy Volunteers *Escalations after independent Data Monitoring Committee review of: 1) Safety, and 2) Target suppression via serum biomarker Single Ascending Dose Repeat Dose 1 mg/kg 2.5 mg/kg 5 mg/kg 10 mg/kg 5 mg/kg wee
Slide 8: PK/PD Model Using Healthy Volunteer Data Guides Dose Selection for Cancer Patients
PK/PD Model Using Biomarker Data from Healthy Volunteers Guides Dose Selection for Studies in Cancer Patients Healthy Volunteer Data Simulations in HV (top) & OC Pts (bottom) Red dashed line shows 50% target engagement Purple envelope represents 10-90% interval Minimum targets based on modeling: 372
Slide 9: AVB500-OC-002: A P1b Study of AVB-S6-500 with Single Agent Chemotherapy in Platinum-Resistant Ovarian Cancer
AVB500-OC-002: A P1b Study of AVB-S6-500 in Combination with Single Agent Chemotherapy in Platinum-Resistant Ovarian Cancer AVB500 (AVB; AVB-S6-500): 10 mg/kg q14 days Pegylated liposomal doxorubicin (PLD): 40 mg/m2 d1; 28-day cycle Paclitaxel (Pac): 80 mg/m2 day 1, day 8, day 15; 28-day cycle Key E
Slide 10: Distribution of Baseline Characteristics and Prognostic Factors (Efficacy Population)
Distribution of Baseline Characteristics and Prognostic Factors (Efficacy Population) Pac arm (n=6) PLD arm (n=6) Age, years median (min, max) 63.5 (55, 82) 66 (53, 81) Prior lines 1 0 3 (50) 2 5 (83) 2 (33) 3 1 (17) 1 (17) Platinum Free Interval > 3mo 4 (67) 4 (67) < 3mo 2 (33) 2 (33) ECOG 0 5 (83)
Slide 11: First Cycle Safety Data for the First Patients in Each Cohort
First Cycle Safety Data for the First Patients in Each Cohort Number of Subjects With (Safety Population) AVB+Pac (n=6) AVB+PLD (n=7) AE 6 (100) 5 (71.4) SAE 0 0 Dose Limiting Toxicity 0 0 Related AE with G>3 0 0 N=3 had Grade 2 infusion reactions with AVB infusion. A premedication regimen (anti-H2,
Slide 12: First Cycle PK and PD Data for the First Patients in Each Cohort
First Cycle PK and PD Data for the First 6 Patients in Each Cohort Serum AVB Conc (ng/mL) AVB+PLD AVB+Pac GAS6 concentrations immediately decreased from baseline levels to BLQ in every patient, and remained BLQ throughout the two-week dosing period AVB500 concentrations did not decrease below 3720 n
Slide 13: Best Response Determined by Investigator-Assessed RECIST for First 12 Patients
Best Response Determined by Investigator-Assessed RECIST for First 12 Patients Response Rate AVB+PLD 33% AVB+Pac 50% Overall 42% Clinical Benefit 58% * 2 Progressive Disease patients (both in Pac arm) are not shown as CTs were not obtainable at time of progression Green = AVB + Pac Blue = AVB + PLD
Slide 14: Current Average Treatment Duration for Responders
Current Average Treatment Duration for Responders is 7 Months = partial response (PR) = progressive disease (PD) Time on Treatment (days) AVB+Pac AVB+PLD 4/5 PRs still ongoing 2 of the 4 continue to receive chemo + AVB 2 of the 4 are currently receiving AVB alone (no more chemotherapy) Company logo
Slide 15: Conclusions Based on Available Data from the First Patients
Conclusions Based on Available Data from the First 12 Patients AVB500 effectively sequesters serum GAS6, the sole ligand for AXL, in platinum-resistant ovarian cancer patients AVB500 administration was not associated with any dose-limiting toxicities nor serious adverse events Infusion reactions mit
Slide 16: Next Steps
Next Steps Phase 2 Study Design ClinicalTrials.gov Identifier: NCT03639246 P1b study expanded to Determine ORR data across larger population Continuously update PK/PD model with additional data to identify optimal AVB500 dose Using Model-Informed Drug Development (MIDD) to guide selection of higher